|
|
|
|
|
|
|
|
|
|
|
|
|
13.10.26 - 00:21
|
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit (PR Newswire)
|
|
|
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff......
|
|
|
12.10.26 - 23:45
|
Teva to Host R&D Day on Wednesday, November 11 in New York City (GlobeNewswire EN)
|
|
|
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy....
|
|
|
|
|
|
|
12.10.26 - 22:51
|
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026 (GlobeNewswire EN)
|
|
|
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook....
|
|
|
|
|
|
|
12.10.26 - 22:33
|
USANA Schedules Third Quarter 2026 Earnings Release and Conference Call (Business Wire)
|
|
|
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2026 results will be released after the close of market on Tuesday, November 3, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, November 4, 2026 at 11:00 a.m. Eastern Time.The call will be broadcast over the Internet and can be accessed at http://ir.usana.com.About USANAUSANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers across 25 global markets. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya ...
|
|
|
12.10.26 - 22:33
|
Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026 (Business Wire)
|
|
|
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2026 (3Q26), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on November 6, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026.
A webcast of the 3Q26 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/.
If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIe96a47a3d2724a5baa1fa1210aa58a13.
Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.
The company suggests participants listening via the web or the conference call sign in or dial in at least 15 ...
|
|
|
|
|
|
|
|
|
|
|
12.10.26 - 22:12
|
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers (GlobeNewswire EN)
|
|
|
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly®AM plus SoC, providing clinical evidence supporting the use of PuraPly®AM in one of the most costly and difficult-to-treat chronic wound populations....
|
|
|
12.10.26 - 22:09
|
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer (Business Wire)
|
|
|
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine (“Katie”) McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.
Ms. McClure brings more than 20 years of experience in transforming innovative medical technologies into sustainable commercial growth through strategic leadership, talent development, physician engagement, and enterprise partnerships. Ms. McClure joins Myomo from Inspire Medical Systems (“Inspire” NASDAQ:INSP), a fast-growing medical technology company for whom she was employed since 2018. During her tenure at Inspire, revenues grew from approximately $50 million to nearly $1 billion and, in the territories under her leadership...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
